

Hemostemix Holds First Meeting of Data Safety Monitoring Board (DSMB)

TORONTO, ONTARIO – AUG 20, 2015 – Hemostemix Inc. (“Hemostemix” or the “Company”) (TSXV: [HEM](#)), a clinical-stage autologous cell-therapy company that has treated 15 of 100 patients in its international phase-2 clinical trial for critical limb ischemia (CLI), announced the first meeting of its Data Safety Monitoring Board (DSMB). Governed by regulations from the National Institutes of Health (NIH), the DSMB is comprised of independent experts who oversee the safety and conduct of the Hemostemix trial.

Experts on the Hemostemix DSMB include:

- Armand Keating, MD, FRCPC, director of the Cell Therapy Program at the Philip S. Orsino Facility for Cell Therapy and professor of medicine at the Princess Margaret Cancer Centre, University of Toronto, Canada
- Richard McLain, biostatistician at PFP Statistical Consulting, LLC, Detroit, Michigan, USA (previously 20-year associate director of Pfizer Global Research & Development, Ann Arbor, Michigan)
- Anthony Comerota, MD, FACS, FACC, director of the Jobst Vascular Institute at ProMedica Toledo Hospital, Toledo, Ohio, USA

“Following the recent Food and Drug Administration clearance of the Company’s Investigational New Drug application to expand our phase-2 trial for CLI to clinical sites across the United States, our top priority continues to be conducting our clinical trial safely,” said Dr. Hardean E. Achneck, vice president of clinical research and operations at Hemostemix. “We feel privileged that the safety of our trial is being monitored by such an outstanding team of prominent physicians and scientists in the fields of vascular surgery, biostatistics, and cell therapy.”

About Critical Limb Ischemia (CLI)

CLI is a severe form of peripheral artery disease (PAD) caused by reduced blood flow to the legs. About half of CLI patients either die or require amputation of the affected limb within one year of diagnosis. Demand for a treatment is on the rise, as CLI predominately affects the growing population aged 50 and older.

About Hemostemix

Hemostemix is a public clinical-stage biotechnology company that develops and commercializes innovative blood-derived cell therapies for medical conditions not adequately addressed by current treatments. Hemostemix Inc. is traded on the TSX Venture Exchange under the trading symbol [HEM](#). For more information, visit hemostemix.com or email office@hemostemix.com.

Contacts:

Hemostemix Inc.

Dr. Elmar Burchardt
President and CEO
Phone: (617) 500-8401

Dr. Rahul Sarugaser
Vice President, Corporate Development
Phone: (647) 919-8820

Neither the TSX Venture Exchange, Inc. nor its Regulation Service Provider (as that term is defined under the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Forward-Looking Statements

This release may contain forward-looking statements. Forward-looking statements are statements that are not historical facts and are generally, but not always, identified by the words “expects,” “plans,” “anticipates,” “believes,” “intends,” “estimates,” “projects,” “potential,” and similar expressions, or that events or conditions “will,” “would,” “may,” “could,” or “should” occur. Although Hemostemix believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results may differ materially from those in forward looking statements. Forward-looking statements are based on the beliefs, estimates and opinions of Hemostemix management on the date such statements were made. Hemostemix expressly disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise.